

-2-

RECEIVED  
CENTRAL FAX CENTER

DEC 22 2006

REMARKS

Claims 1-30 are pending in this application.

**I. Election/Restrictions**

The Office Action indicates that restriction to one of the following invention groups is required under 35 U.S.C. §121:

- I. Claims 1-17, drawn to a unit dosage form comprising atorvastatin, classified in class 4424, subclass 1.13.
- II. Claim 18, drawn to a unit dosage form comprising atorvastatin and another active drug, classified in class 424, subclass 1.13.
- III. Claims 19-26, drawn to method preparing a unit dosage form comprising atorvastatin, classified in class 424, subclass 1.13.
- IV. Claim 27, drawn to a method of preparing a unit dosage form comprising atorvastatin and another active drug, classified in class 424, subclass 1.13.
- V. Claim 28, drawn to a method of treatment, classified in class 424, subclass 1.13.
- VI. Claims 29 and 30, drawn to a kit, classified in class 424, subclass 1.13.

The Applicants hereby elect Group I, encompassing claims 1-17, for prosecution on the merits; and as further explained in the Office Action. The Applicants respectfully reserve the right to file a Divisional application(s) to prosecute the non-elected subject matter.

**II. Conclusion**

The Applicants submit that this application is now in condition for allowance, which allowance is respectfully solicited.


-3-

It is understood by the Applicants that this paper does not require a fee. In the event that a fee is required for this submission, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at 734-622-3831.

Respectfully submitted,

Dated: December 22, 2006



Mehdi Ganjeizadeh

Registration No. 47,585

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Telephone: (734) 622-3831

Facsimile: (734) 622-1553